EMERYVILLE, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, today announced that Andrew Allen, M.D., Ph.D., Co-founder, President and Chief Executive Officer will participate in the “Infectious Disease” panel at the Cowen 42nd Annual Health Care Conference, which is being held virtually from March 7 to 9.
Panel Details
Title: Infectious Disease
Date and Time: Wednesday, March 9th from 10:30 – 11:30 a.m. ET
A live webcast of the panel will be accessible via the Investors & Media section of the company’s website at https://ir.gritstonebio.com/investors/events. An archived replay will be accessible for 30 days following the event.
About Gritstone bio
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases. Gritstone develops its products by leveraging two key pillars—first, a proprietary machine learning-based platform, Gritstone EDGE™, which is designed to predict antigens that are presented on the surface of cells, such as tumor or virally-infected cells, that can be seen by the immune system; and, second, the ability to develop and manufacture potent immunotherapies utilizing these antigens to potentially drive the patient’s immune system to specifically attack and destroy disease-causing cells. The company’s lead oncology programs include an individualized neoantigen-based immunotherapy, GRANITE, and an “off-the-shelf” shared neoantigen-based immunotherapy, SLATE, which are being evaluated in clinical studies. Within its infectious disease pipeline, Gritstone is advancing CORAL, a COVID-19 program to develop a second-generation vaccine, with support from departments within the National Institutes of Health (NIH), the Bill & Melinda Gates Foundation, the Coalition for Epidemic Preparedness Innovations (CEPI) and through a license agreement with La Jolla Institute for Immunology. Additionally, the company has a global collaboration for the development of a therapeutic HIV vaccine with Gilead Sciences. For more information, please visit gritstone.com.
Gritstone Contacts
Media:
Dan Budwick
1AB
(973) 271-6085
dan@1abmedia.com
Investors:
George E. MacDougall
Director, Investor Relations & Corporate Communications
Gritstone bio
Ir@gritstone.com
